Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Neurocrine Bioscienc (NQ: NBIX ) 119.36 -1.28 (-1.07%) Streaming Delayed Price Updated: 2:32 PM EDT, Sep 10, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Headline News about Neurocrine Bioscienc < Previous 1 2 3 4 5 6 7 8 9 Next > Analyst Bullish On Gene Therapy-Focused Voyager Therapeutics Sees Best In Class Potential For Its Neurogenetic Medicine Platform March 19, 2024 Unlock potential with Voyager Therapeutics as HC Wainwright initiates coverage highlights its TRACER capsid platform, promising CNS-targeted gene therapies and strategic partnerships driving long-term... Via Benzinga Madrigal Pharmaceuticals Stock Hits 80-Plus Relative Strength Rating Benchmark March 18, 2024 On Monday, Madrigal Pharmaceuticals stock hit a key technical milestone, seeing its Relative Strength Rating jump to 83 from 69 a day ago. Via Investor's Business Daily AI Plays HubSpot, Arista Networks Lead Five Stocks Near Buy Points In Classic Base March 16, 2024 Three of the featured stocks are closing in on record highs. Via Investor's Business Daily Topics Artificial Intelligence Exposures Artificial Intelligence Why Quality-Oriented Investors Should Consider NASDAQ:NBIX. March 15, 2024 Analyzing the Quality Characteristics of NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX). Via Chartmill NASDAQ:NBIX is probably undervalued for the fundamentals it is displaying. March 14, 2024 When you look at NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX), it's hard to ignore the strong fundamentals, especially considering its likely undervaluation. Via Chartmill Decoding 8 Analyst Evaluations For Neurocrine Biosciences March 13, 2024 Via Benzinga Is NASDAQ:NBIX on the Verge of a Major Breakout as a Strong Growth Stock? February 28, 2024 Why NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) Is a Promising High-Growth Stock in the Midst of Consolidation. Via Chartmill Breaking Down Neurocrine Biosciences: 8 Analysts Share Their Views February 08, 2024 Via Benzinga In-Depth Examination Of 8 Analyst Recommendations For Neurocrine Biosciences March 13, 2024 Via Benzinga 3 Cutting-Edge Biotech Stocks Sitting on the Brink of Success March 06, 2024 With excellent financial health and great prospects, these three biotech stocks just may be the the next stars of the sector. Via InvestorPlace Amicus Therapeutics Stock Sees RS Rating Improve To 74 March 05, 2024 In a welcome move, Amicus Therapeutics stock saw its Relative Strength Rating rise from 69 to 74 on Tuesday. Via Investor's Business Daily Investors should take note of NASDAQ:NBIX, a growth stock that remains attractively priced. February 28, 2024 For those who appreciate growth without the sticker shock, NASDAQ:NBIX is worth considering. Via Chartmill Beam Therapeutics Stock Jumps To Higher RS Level On Earnings Beat February 27, 2024 Beam Therapeutics stock saw a welcome improvement to its Relative Strength (RS) Rating on Tuesday, with an upgrade from 73 to 81. Via Investor's Business Daily Agios Pharmaceuticals Stock Earns RS Rating Upgrade; Hits Key Benchmark February 23, 2024 Agios Pharmaceuticals shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 65 to 84. Via Investor's Business Daily Earnings Scheduled For February 7, 2024 February 07, 2024 Companies Reporting Before The Bell • Madison Square Garden (NYSE:MSGE) is expected to report quarterly loss at $0.80 per share on revenue of $301.83 million. Via Benzinga Exploring the Growth Potential of NASDAQ:NBIX as It Nears a Breakout. February 07, 2024 Is NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) on the Verge of a Major Breakout as a Strong Growth Stock? Via Chartmill Earnings Outlook For Neurocrine Biosciences February 06, 2024 Via Benzinga Unveiling 13 Analyst Insights On Neurocrine Biosciences January 23, 2024 Via Benzinga Beam Therapeutics Stock Shows Healthy Relative Strength Improvement February 16, 2024 In a welcome move, Beam Therapeutics stock saw its Relative Strength (RS) Rating rise from 67 to 76 on Friday. Via Investor's Business Daily Alkermes Stock Gets RS Rating Upgrade; Profits Surge February 15, 2024 In a welcome move, biotech Alkermes stock saw its Relative Strength Rating improve from 69 to 75 on Thursday. Via Investor's Business Daily CRISPR Therapeutics Stock Shows Rising Relative Strength, Hits 90+ February 13, 2024 CRISPR Therapeutics shows improving price performance, earning an upgrade to its IBD Relative Strength Rating. Via Investor's Business Daily Why This Teva Pharmaceutical Analyst Is Turning Bullish On The Austedo Franchise February 12, 2024 Shares of Teva Pharmaceutical Industries Ltd (NYSE: TEVA) climbed in early trading on Monday, after several analysts raised their forecasts. Via Benzinga Amicus Therapeutics Stock Sees Improved Relative Strength Rating February 09, 2024 In a welcome move, Amicus Therapeutics stock saw its Relative Strength Rating rise from 64 to 78 on Friday. Via Investor's Business Daily Stock Market Hits Highs As AI Plays Arm, Palantir Skyrocket: Weekly Review February 08, 2024 The S&P 500 hit 5,000. Arm, Palantir and Cloudflare rose sharply. Via Investor's Business Daily Topics Artificial Intelligence Stocks Exposures Artificial Intelligence US Equities NASDAQ:NBIX is not too expensive for the growth it is showing. February 06, 2024 While growth is established for NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX), the stock's valuation remains reasonable. Via Chartmill NASDAQ:NBIX, a growth stock which is not overvalued. January 15, 2024 NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) stands out as a growth opportunity that won't break the bank. Via Chartmill NASDAQ:NBIX, a strong growth stock, setting up for a breakout. January 12, 2024 Why NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) Is a Standout High-Growth Stock in a Consolidation Phase. Via Chartmill Eli Lilly, Crispr, Biogen Lead Pharma And Biotech Stocks To Great Expectations In 2024 January 05, 2024 Between buyouts, obesity drugs and neuroscience progress, biotech stocks stand to gain. Via Investor's Business Daily VYGR Stock Alert: The $1.2 Billion Reason Voyager Therapeutics Is Up Today January 02, 2024 VYGR stock is in focus as analysts expect more pharma deals in 2024, although some think these deals will be sunk by the Biden administration. Via InvestorPlace Amgen Stock Sees Relative Strength Rating Improve To 74 December 29, 2023 Amgen stock saw a positive improvement to its Relative Strength (RS) Rating on Friday, with an upgrade from 69 to 74. Via Investor's Business Daily < Previous 1 2 3 4 5 6 7 8 9 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.